Provectus Biopharmaceuticals (PVCT) shares have slumped after the company announced the pricing of its "best efforts" public equity offering. PVCT is offering of 240,000 shares of Series B Convertible Preferred Stock, initially convertible into an aggregate of 24 million shares of common stock, and warrants to purchase up to 24 million shares of common at a price of $25 for a combination of one Series B share and one immediately exercisable five-year warrant to purchase one share of common at $0.275.